Summit Therapeutics (SMMT) Depreciation and Depletion (2017 - 2026)
Summit Therapeutics (SMMT) posted quarterly Depreciation and Depletion of $46000.0 for Q2 2026, up 24.32% year-on-year from $37000.0 in Q2 2025, and up 4.55% on a QoQ basis from $44000.0 in Q1 2026.
Summit Therapeutics (SMMT) Depreciation and Depletion (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has reported Depreciation and Depletion for 10 consecutive years, with $46000.0 the latest figure, recorded in Q2 2026.
- Quarterly Depreciation and Depletion rose 24.32% year-over-year to $46000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $174000.0 (up 67.31% YoY) and the FY2025 annual result came in at $146000.0, up 64.04% from the prior year.
- Depreciation and Depletion improved to $46000.0 in Q2 2026 per SMMT's latest filing, from $44000.0 in the prior quarter.
- Over the last five years, Depreciation and Depletion for SMMT reached as high as $99000.0 in Q2 2022 and fell as low as $20000.0 in Q2 2024.
- A 5-year average of $48444.4 and a median of $42000.0 in 2025 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2024 — Depreciation and Depletion plunged 70.0% — and 2025, when it jumped 110.0%.
- Year by year, Depreciation and Depletion stood at $88000.0 in 2022, then tumbled by 65.91% to $30000.0 in 2023, then slipped by 26.67% to $22000.0 in 2024, then jumped by 90.91% to $42000.0 in 2025, then rose by 9.52% to $46000.0 in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $46000.0, $44000.0, and $42000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 39.39 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Summit Therapeutics | 11.62 Bn | 11.03 Bn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46,000.00 |
| Jun 30, 2026 | 46,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |